
Opinion|Videos|January 5, 2026
Real-World Results for Lenvatinib Plus Pembrolizumab in Endometrial Cancer
Author(s)Ramez N. Eskander, MD
Real-world data reinforces the efficacy and tolerability of lenvatinib and pembrolizumab for treating recurring endometrial cancer.
Advertisement
Episodes in this series

Ramez N. Eskander, MD, highlights findings from a real-world analysis of lenvatinib/pembrolizumab versus single-agent chemotherapy in patients with advanced endometrial carcinoma. He also discusses these outcomes in the context of prior clinical research exploring this regimen.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































